177 related articles for article (PubMed ID: 12033987)
1. A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273].
Collantes E; Curtis SP; Lee KW; Casas N; McCarthy T; Melian A; Zhao PL; Rodgers DB; McCormick CL; Lee M; Lines CR; Gertz BJ;
BMC Fam Pract; 2002 May; 3():10. PubMed ID: 12033987
[TBL] [Abstract][Full Text] [Related]
2. A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis.
Matsumoto AK; Melian A; Mandel DR; McIlwain HH; Borenstein D; Zhao PL; Lines CR; Gertz BJ; Curtis S;
J Rheumatol; 2002 Aug; 29(8):1623-30. PubMed ID: 12180720
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of two doses of etoricoxib, a COX-2 selective non-steroidal anti-inflammatory drug (NSAID), in the treatment of Rheumatoid Arthritis in a double-blind, randomized controlled trial.
Bickham K; Kivitz AJ; Mehta A; Frontera N; Shah S; Stryszak P; Popmihajlov Z; Peloso PM
BMC Musculoskelet Disord; 2016 Aug; 17():331. PubMed ID: 27502582
[TBL] [Abstract][Full Text] [Related]
4. Etoricoxib versus naproxen in patients with rheumatoid arthritis: a prospective, randomized, comparator-controlled 121-week trial.
Matsumoto A; Melian A; Shah A; Curtis SP
Curr Med Res Opin; 2007 Sep; 23(9):2259-68. PubMed ID: 17697449
[TBL] [Abstract][Full Text] [Related]
5. Association between health-related quality of life and clinical efficacy endpoints in rheumatoid arthritis patients after four weeks treatment with anti-inflammatory agents.
Eichler HG; Mavros P; Geling O; Hunsche E; Kong S
Int J Clin Pharmacol Ther; 2005 May; 43(5):209-16. PubMed ID: 15906586
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of valdecoxib in treating the signs and symptoms of severe rheumatoid arthritis: a 12-week, multicenter, randomized, double-blind, placebo-controlled study.
Gibofsky A; Rodrigues J; Fiechtner J; Berger M; Pan S
Clin Ther; 2007 Jun; 29(6):1071-85. PubMed ID: 17692722
[TBL] [Abstract][Full Text] [Related]
7. A randomized, clinical trial to assess the relative efficacy and tolerability of two doses of etoricoxib versus naproxen in patients with ankylosing spondylitis.
Balazcs E; Sieper J; Bickham K; Mehta A; Frontera N; Stryszak P; Popmihajlov Z; Peloso PM
BMC Musculoskelet Disord; 2016 Oct; 17(1):426. PubMed ID: 27737664
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis.
Reginster JY; Malmstrom K; Mehta A; Bergman G; Ko AT; Curtis SP; Reicin AS
Ann Rheum Dis; 2007 Jul; 66(7):945-51. PubMed ID: 17142385
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study.
van der Heijde D; Baraf HS; Ramos-Remus C; Calin A; Weaver AL; Schiff M; James M; Markind JE; Reicin AS; Melian A; Dougados M
Arthritis Rheum; 2005 Apr; 52(4):1205-15. PubMed ID: 15818702
[TBL] [Abstract][Full Text] [Related]
10. Further assessment of the clinically effective dose range of etoricoxib: a randomized, double-blinded, placebo-controlled trial in rheumatoid arthritis.
Greenwald M; Peloso PM; Mandel D; Soto O; Mehta A; Frontera N; Boice JA; Zhan XJ; Curtis SP
Curr Med Res Opin; 2011 Oct; 27(10):2033-42. PubMed ID: 21905970
[TBL] [Abstract][Full Text] [Related]
11. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.
Hunt RH; Harper S; Watson DJ; Yu C; Quan H; Lee M; Evans JK; Oxenius B
Am J Gastroenterol; 2003 Aug; 98(8):1725-33. PubMed ID: 12907325
[TBL] [Abstract][Full Text] [Related]
12. Analgesic efficacy of etoricoxib in primary dysmenorrhea: results of a randomized, controlled trial.
Malmstrom K; Kotey P; Cichanowitz N; Daniels S; Desjardins PJ
Gynecol Obstet Invest; 2003; 56(2):65-9. PubMed ID: 12900528
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal numbers-needed-to-treat (NNT) for achieving various levels of analgesic response and improvement with etoricoxib, naproxen, and placebo in ankylosing spondylitis.
Peloso PM; Gammaitoni A; Smugar SS; Wang H; Moore AR
BMC Musculoskelet Disord; 2011 Jul; 12():165. PubMed ID: 21767407
[TBL] [Abstract][Full Text] [Related]
14. A placebo and active comparator-controlled trial of rofecoxib for the treatment of rheumatoid arthritis.
Geusens PP; Truitt K; Sfikakis P; Zhao PL; DeTora L; Shingo S; Lau CS; Kalla A; Tate G
Scand J Rheumatol; 2002; 31(4):230-8. PubMed ID: 12369656
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: A randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial.
Leung AT; Malmstrom K; Gallacher AE; Sarembock B; Poor G; Beaulieu A; Castro R; Sanchez M; Detora LM; Ng J
Curr Med Res Opin; 2002; 18(2):49-58. PubMed ID: 12017209
[TBL] [Abstract][Full Text] [Related]
16. Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib.
Hunt RH; Harper S; Callegari P; Yu C; Quan H; Evans J; James C; Bowen B; Rashid F
Aliment Pharmacol Ther; 2003 Jan; 17(2):201-10. PubMed ID: 12534404
[TBL] [Abstract][Full Text] [Related]
17. Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials.
Curtis SP; Ng J; Yu Q; Shingo S; Bergman G; McCormick CL; Reicin AS
Clin Ther; 2004 Jan; 26(1):70-83. PubMed ID: 14996519
[TBL] [Abstract][Full Text] [Related]
18. Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective Inhibitor etoricoxib.
Curtis SP; Ko AT; Bolognese JA; Cavanaugh PF; Reicin AS
Curr Med Res Opin; 2006 Dec; 22(12):2365-74. PubMed ID: 17265571
[TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind, parallel-group study comparing the analgesic effect of etoricoxib to placebo, naproxen sodium, and acetaminophen with codeine using the dental impaction pain model.
Malmstrom K; Kotey P; Coughlin H; Desjardins PJ
Clin J Pain; 2004; 20(3):147-55. PubMed ID: 15100590
[TBL] [Abstract][Full Text] [Related]
20. Etoricoxib in the treatment of osteoarthritis over 52-weeks: a double-blind, active-comparator controlled trial [NCT00242489].
Curtis SP; Bockow B; Fisher C; Olaleye J; Compton A; Ko AT; Reicin AS
BMC Musculoskelet Disord; 2005 Dec; 6():58. PubMed ID: 16321158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
